

Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)

Technology appraisal guidance

Published: 22 July 2015

www.nice.org.uk/guidance/ta351

© NICE 2025. All rights reserved. Subject to Notice of rights (<https://www.nice.org.uk/terms-and-conditions#notice-of-rights>).

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. This is because The Medicines Company did not provide an evidence submission. They consider that there is not enough evidence to provide an evidence submission for this appraisal.

Information

If NHS organisations wish to consider cangrelor for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-1341-1